InvestorsHub Logo
Followers 3
Posts 281
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Sunday, 03/05/2023 10:00:58 AM

Sunday, March 05, 2023 10:00:58 AM

Post# of 149
Good news for Karyopharm.
Incyte ending phase 3 program evaluating myelofibrosis candidate parsaclisib.
Incyte (NASDAQ:INCY) said it would end a phase 3 program examining its myelofibrosis candidate parsaclisib with Jakafi (ruxolitinib) after an interim analysis showed the study was unlikely to meet its primary endpoint.
https://seekingalpha.com/news/3944167-incyte-ending-phase-3-program-evaluating-myelofibrosis-candidate-parsaclisib
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KPTI News